HISTORICAL BACKGROUND OF GSM

The origins of the GSM trace back to a previous corporation of the same initials formed in 1990 by Jerome B. Block, M.D., Steven Evans, M.S., and Henry T. Lynch, M.D. as an Omaha-based clinical services corporation.  They had previously pioneered the development of a clinical service called the Hereditary Cancer Consulting Service (HCCS) which enabled cancer centers to assess both cancer patients and unaffected concerned individuals for inherited cancer risk and advise them (and any relatives whose health would or could be implicated) as to suitable health screening procedures tailored for their particular identified risk.  This service drew upon the decades of experience of Dr. Lynch at the Creighton (University) Medical School-based Hereditary Cancer Institute in Omaha as well as upon artificial-intelligence-based expert system software to automate significant components of the process.  After several years of successful beta-site clinical testing, the predecessor company introduced HCCS into community cancer centers around the country and operated as an independent company for four years.

 

In 1993, the predecessor company was acquired by and merged into Oncormed, Inc. of Gaithersburg, Maryland, a biotechnology firm providing genetic testing throughout the country.  Oncormed further refined the HCCS program and negotiated additional contracts for its use at cancer centers throughout the United States.  In October of 1998, Gene Logic, Inc. which focused on gene detection, acquired Oncormed.  Gene Logic elected to sell the service, which it viewed as extraneous to its core business, back to its original developers, who formed the new GSM Company for that purpose.   HCCS is now in its 10th year of providing hereditary cancer assessment service at cancer centers throughout the United States and abroad (the Republic of China). 

 

In 1999, the mission of GSM was expanded to include a program of service for general cancer risk in addition to its historical mission addressing hereditary cancer.  The Company developed a general cancer risk evaluation form, and in conjunction, assessed the nutrition supplements scientific literature to identify those nutritional elements for which there is compelling evidence in the scientific literature to indicate these elements can have a positive effect on those factors associated with cancer risk reduction.  The Company now manufactures this 14 ingredient supplement, called Formula #18, which is correlated to the cancer risk questionnaire it developed.

 

The Company‚Äôs general cancer risk assessment, supplement formulation, and ongoing evaluation is part of an international clinical trial it has launched to evaluate and document the efficacy of its formulation.  The Company is working to enroll several thousand individuals in the United States and elsewhere, which would make its clinical trial the largest of its kind in the world.

 

Finally, GSM will begin to identify additional complementary health care products and services which are of superior quality and effectiveness and which may thus be recommended.